Lotte Biologics signs antibody drug CMO deal with UK’s Ottimo Pharma

Lotte Biologics CEO James Park

BOSTON – Lotte Biologics Co. has signed a deal to manufacture an antibody therapy for British biotech startup Ottimo Pharma as the South Korean biopharmaceutical company moves to expand its presence in the global supply chain.

Lotte Biologics, the drug consignment development and production unit of Korean conglomerate Lotte Group, signed the contract during the annual BIO International Convention, which began on Monday in Boston, Massachusetts.

Lotte didn’t disclose the financial terms of the contract.

Under the deal, known as contract manufacturing organization (CMO), Lotte will produce Ottimo Pharma’s dual-action antibody drug Jankistomig at its Syracuse bio campus in New York – a facility it acquired from Bristol Myers Squibb (BMS) in 2023.

Lotte Biologics CEO James Park (third from right) and Ottimo Pharma Vice President Joseph Shultz (third from left) pose for a photo after signing a CMO deal during the BIO International Convention 2025 in Boston

Ottimo Pharma’s Jankistomig is a one-of-a-kind PD1/VEGFR2 dual pathway antibody designed to extend the lives of patients living with cancer.

Production is set to begin as early as July, with the initial clinical batches to be used in human trials of the drug, targeting both PD1 and VEGFR2 proteins – pathways associated with immune suppression and tumor growth, respectively.

Jankistomig is believed to be the first such drug candidate globally.

“This is potentially a blockbuster-class drug,” said James Park, chief executive of Lotte Biologics, during a press briefing on the sidelines of the convention. “It combines immunotherapy and targeted therapy mechanisms into a single molecule, an innovation that could reshape future cancer treatments.”

Lotte Biologics aims to join the global top 10 CDMO firms by 2030 (Screenshot captured from its website)

SECOND DEAL SINCE APRIL’S ADC CONTRACT

The agreement marks Lotte Biologics’ second CMO deal since April, when it signed its first contract with an undisclosed Asian company to manufacture an antibody-drug conjugate (ADC).

ADCs, often described as “guided missiles” for cancer therapy, deliver cytotoxic agents directly to tumors with minimal damage to healthy tissue.

Park said Lotte is in last-stage negotiations with three additional clients and could announce “one or two ADC-related contracts within a month.”

Lotte Biologics’ pharmaceuticals production plant in Syracuse, New York

Lotte is building a 120,000-liter biomanufacturing facility in Songdo, Incheon, as its high-volume production hub from 2027 to accommodate CMO and CDMO, or contract development and manufacturing organization, requests.

SYRACUSE PLANT: STRATEGIC BRIDGE FOR CLIENTS

The Syracuse site, by contrast, acts as a strategic bridge for partnerships with global biotech clients, particularly those looking to mitigate rising tariff risks and strengthen onshore parts of their supply chains, according to Lotte.

Lotte Biologics is a latecomer to the Korean CDMO market, which is dominated by its larger rivals such as Samsung Biologics Co. and SK Biopharmaceuticals Co.

Bird’s-eye view of Lotte Biologics’ plants in Songdo, Incheon, South Korea (Courtesy of Lotte)

“There is growing interest from biopharma companies seeking to move production back to the US due to tariff concerns,” said Park. “Lotte is currently the only Korean CDMO with antibody-drug conjugate production capabilities on US soil, and that’s giving us a competitive edge.”

Last year, Lotte said it aims to achieve 1.5 trillion won ($1.1 billion) in annual sales by 2030, becoming one of the global top 10 contract drugmakers by then.

By Hyun-Ah Oh

5hyun@hankyung.com

In-Soo Nam edited this article.

Latest News from Korea

  • TXT weathers the storm in ‘Steal The Wind’
    Amid thunderous applause, the five boys of K-pop group TOMORROW X TOGETHER (TXT) emerge from a sea of fog, surrounded by a cloud of smoke and ushered in by pounding drums. Soobin, Yeonjun, Beomgyu, Taehyun and Hueningkai bring you directly to the eye of the storm, as unnerving synths fill your senses. The opening song “Storm Is…” sets the tone… Read more: TXT weathers the storm in ‘Steal The Wind’
  • 롯데건설 ‘청담 르엘’, 조경대상 국가유산청장상 수상
    롯데건설은 서울 강남구 ‘청담 르엘’에 조성한 단지 조경 ‘Nature Drape 청담’으로 2026 대한민국 조경대상에서 국가유산청장상을 수상했다고 15일 밝혔다. 대한민국 조경대상은 국토교통부와 환경조경발전재단이 공동 주최하는 조경 분야 최고 권위의 상이다. 2001년 시작해 올해로 16회차를 맞이했으며 쾌적한 생활환경을 창출하고 국민 삶의 질 향상에 기여한 우수 조경 사례를 발굴해 시상한다. 롯데건설은 지난해 산림청장상을 수상한 데 이어 올해까지 2년 연속 수상 명단에 이름을 올렸다.… Read more: 롯데건설 ‘청담 르엘’, 조경대상 국가유산청장상 수상
  • 풀무원 임직원, 업무용 AI 에이전트 직접 만든다
    풀무원이 임직원이 직접 인공지능(AI) 도구를 개발해 업무 효율을 높이는 ‘AX(AI 전환) 해커톤’을 개최했다.  지난 12일과 13일 양일간 서울 강남구 수서 본사에서 열린 이번 해커톤은 풀무원이 최근 구축한 ‘AX 테크 플랫폼’의 활용을 확대하기 위해 마련됐다. 지난 13일 풀무원 수사 본사에서 열린 ‘AX 해커톤’에서 대상 수상자(오른쪽)가 이우봉 총괄CEO와 기념 촬영하고 있다. 풀무원은 개발 지식이 부족한 비개발 직군 실무자들도 참여할 수 있도록 체계적인… Read more: 풀무원 임직원, 업무용 AI 에이전트 직접 만든다
  • 풀무원, COP31서 ‘지속가능식단’ 성과 발표
    풀무원은 지난 12일(현지시간) 튀르키예 안탈리아에서 열린 ‘제31차 유엔기후변화협약 당사국총회(COP31)’ 한국홍보관에 참여해 지속가능식생활 추진 사례와 성과를 발표했다. 풀무원은 이번 행사에서 지속가능식단의 환경적·영양적 효과를 검증한 연구 결과를 중점적으로 소개했다. 미국영양학회 국제학술대회에서 발표된 해당 연구는 풀무원기술원 구내식당의 식단을 전과정평가(LCA) 방식으로 분석한 결과다. 풀무원 관계자가 지난 12일(현지시간) COP31 한국홍보관에서 생산부터 소비까지 이어지는 지속가능식생활 추진 사례를 발표하고 있다. 분석 결과에 따르면 지속가능식단의 한 끼당 탄소발자국은… Read more: 풀무원, COP31서 ‘지속가능식단’ 성과 발표
  • 쿠팡, ‘가전·디지털 블랙프라이데이’ 개최
    쿠팡은 오는 16일부터 29일까지 인기 가전 및 디지털 기기를 파격적인 특가에 선보이는 ‘가전·디지털 블랙프라이데이’ 기획전을 운영한다. 이번 행사에는 인텔, HP, 쿠첸, TCL 등 대중적인 브랜드부터 뱅앤올룹슨, 포칼, 캠브리지 등 프리미엄 오디오 브랜드까지 참여해 선택의 폭을 넓혔다. 특히 삼성전자의 최신 ‘갤럭시 탭 S12’ 구매 시 카드 할인과 최대 5만 원의 쿠팡캐시 적립 혜택을 제공하며, JBL 음향 기기는 와우회원 전용 쿠폰으로 가격… Read more: 쿠팡, ‘가전·디지털 블랙프라이데이’ 개최

Latest Entertainment from Korea

Learn People & History of Korea